K R Hess

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Effect of HER2 status on distant recurrence in early stage breast cancer
    Kenneth R Hess
    Departments of Biostatistics KRH and Breast Medical Oncology FJE, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
    Breast Cancer Res Treat 137:449-55. 2013
  2. ncbi EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment
    Yuanjie Hu
    Department of Biological Chemistry, University of California Irvine, 5171 California Ave, Suite 150, Irvine, CA 92697, USA
    Mol Cancer 10:123. 2011
  3. ncbi Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
    JHERI J DUPART
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer 8:99. 2009
  4. ncbi Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
  5. ncbi Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
  6. ncbi Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 7:106. 2007
  7. ncbi Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
    Kenneth R Hess
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA
    BMC Bioinformatics 12:463. 2011
  8. ncbi Adult glioma incidence trends in the United States, 1977-2000
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2293-9. 2004
  9. ncbi Estrogen receptors and distinct patterns of breast cancer relapse
    Kenneth R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4409, USA
    Breast Cancer Res Treat 78:105-18. 2003
  10. ncbi Microarrays: handling the deluge of data and extracting reliable information
    K R Hess
    Dept of Biostatistics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 447, Houston, TX 77030 4009, USA
    Trends Biotechnol 19:463-8. 2001

Collaborators

Detail Information

Publications96

  1. ncbi Effect of HER2 status on distant recurrence in early stage breast cancer
    Kenneth R Hess
    Departments of Biostatistics KRH and Breast Medical Oncology FJE, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
    Breast Cancer Res Treat 137:449-55. 2013
    ..For liver and distant lymph node recurrences, there was a significant effect of HER2 status that did not change with time or HR status. For lung recurrences, rates did not significantly vary with HER2 status...
  2. ncbi EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment
    Yuanjie Hu
    Department of Biological Chemistry, University of California Irvine, 5171 California Ave, Suite 150, Irvine, CA 92697, USA
    Mol Cancer 10:123. 2011
    ..There are conflicting reports regarding the function of EFEMP1 in different cancer types. In this study, we sought to evaluate the role of EFEMP1 in malignant glioma biology...
  3. ncbi Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
    JHERI J DUPART
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer 8:99. 2009
    ..To test this hypothesis, we manipulated IGFBP3 levels in two imatinib-responsive GIST cell lines and observed cell viability after drug treatment...
  4. ncbi Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  5. ncbi Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
    ....
  6. ncbi Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Cancer 7:106. 2007
    ..To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials...
  7. ncbi Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
    Kenneth R Hess
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA
    BMC Bioinformatics 12:463. 2011
    ..Prediction models were trained to identify which cases had been perturbed. Performance was estimated using Monte-Carlo cross validation...
  8. ncbi Adult glioma incidence trends in the United States, 1977-2000
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2293-9. 2004
    ..A more complete understanding of adult glioma incidence trends might provide indications of risk factors for gliomas and contribute to the search for improved therapies...
  9. ncbi Estrogen receptors and distinct patterns of breast cancer relapse
    Kenneth R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4409, USA
    Breast Cancer Res Treat 78:105-18. 2003
    ..We conducted an analysis of prospectively collected data to compare the clinical behavior of ER-negative versus ER-positive tumors with respect to rates and sites of recurrence...
  10. ncbi Microarrays: handling the deluge of data and extracting reliable information
    K R Hess
    Dept of Biostatistics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 447, Houston, TX 77030 4009, USA
    Trends Biotechnol 19:463-8. 2001
    ..Our goal is to point out some of the problems that must be overcome before this promising technology can achieve its full potential...
  11. ncbi Statistical issues in clinical trial design
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 447, Houston, TX 77030 4009, USA
    Curr Oncol Rep 9:55-9. 2007
    ....
  12. ncbi Metastatic patterns in adenocarcinoma
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer 106:1624-33. 2006
    ..The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns...
  13. ncbi Hazard function estimators: a simulation study
    K R Hess
    Department of Biomathematics, Box 237, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030 4095, USA
    Stat Med 18:3075-88. 1999
    ....
  14. ncbi Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 101:615-20. 2009
    ....
  15. ncbi Identifying differentially expressed genes in cDNA microarray experiments
    K A Baggerly
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Comput Biol 8:639-59. 2001
    ..Log ratios are scaled by the standard deviations given by these functions, giving model-based versions of Studentization. An example is given...
  16. ncbi Cognitive function as a predictor of survival in patients with recurrent malignant glioma
    C A Meyers
    Departments of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:646-50. 2000
    ..To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors...
  17. ncbi Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells
    Guido M Sclabas
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:440-9. 2005
    ..Our results also imply that TrkB receptor may be a novel therapeutic target for pancreatic cancer...
  18. ncbi Phase I study of recombinant human endostatin in patients with advanced solid tumors
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3792-803. 2002
    ..rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with activity in preclinical models. Evidence of minor antitumor activity was observed and further studies are indicated...
  19. ncbi Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
    ..Carboplatin plus erlotinib is well tolerated but has modest activity in unselected patients. Future trials should be stratified based on optimal molecular or clinical characteristics...
  20. ncbi Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
    V A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:58-66. 2002
    ..To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with i.v. carboplatin for patients with previously untreated anaplastic gliomas...
  21. ncbi Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration
    T M Breslin
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:123-32. 2001
    ....
  22. ncbi Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..72 in the validation set and outperformed other prediction tools (P = .02). CONCLUSION: Our nomograms predict pCR accurately and can serve as a basis to integrate future molecular markers into a clinical prediction model...
  23. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..CONCLUSIONS: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers...
  24. ncbi 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme
    Siew-Ju See
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 6:253-8. 2004
    ..This data supports the use of cRA in such patients, but its further evaluation in larger, prospective, controlled studies with or without other noncytotoxic and cytotoxic agents may be warranted...
  25. ncbi Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
    ..This drug combination met phase II study criteria; further study in recurrent patients with GBM might be warranted. Further study of therapy-induced joint pain is necessary...
  26. ncbi Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010
    ..We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility...
  27. ncbi Comparison of kidney weight and volume to selected anatomical parameters in the adult female rhesus monkey (Macaca mulatta)
    L R Hill
    Department of Veterinary Medicine and Surgery, The University of Texas M D Anderson Cancer Center, Houston, USA
    J Med Primatol 28:67-72. 1999
    ..We did find that all apparently normal adult female rhesus monkeys typically have similar sized kidneys. This information is useful in that it reduces concerns about consistency in experimental subjects...
  28. ncbi The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival
    Yi-Hong Zhou
    Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3369-75. 2003
    ....
  29. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  30. ncbi Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
    Y Delpech
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res Treat 135:619-27. 2012
    ..001). Low Ki67 expression in the primary tumor is associated with higher clinical benefit and longer time to progression on first-line endocrine therapy and longer survival after metastatic recurrence...
  31. ncbi Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines
    K R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Mol Med 8:183-8. 2001
    ....
  32. ncbi Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  33. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  34. ncbi Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
    ..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG...
  35. ncbi Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4107-15. 2006
    ..In patients who have experienced a CE, additional treatment with trastuzumab can be considered after recovery of cardiac function...
  36. ncbi Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus
    Hideaki Ito
    Department of Neurosurgery, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 98:625-36. 2006
    ..001). CONCLUSIONS: hTERT-Ad may kill telomerase-positive cancer cells by inducing autophagic cell death...
  37. ncbi Overexpression of synuclein-gamma in pancreatic adenocarcinoma
    Zhongkui Li
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, PO Box 424, Houston, TX 77030, USA
    Cancer 101:58-65. 2004
    ..To identify the gene expression profile of pancreatic carcinoma, an important step in the process of developing new diagnostic and therapeutic strategies, the authors investigated the alteration of gene expression in this disease...
  38. ncbi Clinical trial design for microarray predictive marker discovery and assessment
    L Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Oncol 15:1731-7. 2004
    ..This manuscript reviews methodological and statistical issues relevant to clinical trial design to discover and validate multigene predictors of response to therapy...
  39. ncbi Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  40. ncbi Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  41. ncbi Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 13:6080-6. 2007
    ..We examined if supervised analysis of gene expression data from phase II studies could identify HER-2 overexpression as a predictor of response to trastuzumab...
  42. ncbi Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology Unit 426, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 24:1720-8. 2006
    ..Our goal was to determine whether single nucleotide polymorphisms (SNPs) in DNA repair genes influence the clinical outcome of pancreatic cancer...
  43. ncbi Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
    ....
  44. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  45. ncbi Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  46. ncbi Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells
    Hiroshi Aoki
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    FASEB J 21:2918-30. 2007
    ..0065 and P=0.043, respectively). These results indicate that T-oligos stimulate the induction of nonapoptotic autophagic also known as type II programmed cell death and are thus promising in the treatment of malignant glioma...
  47. ncbi A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  48. ncbi Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:3094-103. 2005
    ..To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center...
  49. ncbi Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3804-14. 2002
    ..We present the initial results of a dose-finding clinical trial of recombinant human endostatin (rh-Endo) that examined potential surrogates for response to antiangiogenic therapy...
  50. ncbi Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:4247-54. 2003
    ..In the study described here, we tested in mouse models a vaccine consisting of a peptide encompassing the tumor-specific mutated segment of EGFRvIII (PEP-3) conjugated to keyhole limpet hemocyanin [KLH (PEP-3-KLH)]...
  51. ncbi Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  52. ncbi Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression
    Christina A Meyers
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Neuro Oncol 5:89-95. 2003
    ..New drugs that slow the cognitive decline of brain tumor patients may be of clinical benefit regardless of the impact on overall survival...
  53. ncbi Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
    ....
  54. ncbi Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer
    Xiaoqun Dong
    Department of Gastrointestinal Medical Oncology, Surgical Oncology, Pathology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:1592-9. 2009
    ..DNA mismatch repair (MMR) is critical in maintaining genomic stability and may modulate the cellular response to gemcitabine. We hypothesized that genetic variations in MMR may affect the clinical outcome of patients with pancreatic cancer...
  55. ncbi Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
    Eric L Chang
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 10:1037-44. 2009
    ..We proposed that the learning and memory functions of patients who undergo SRS plus WBRT are worse than those of patients who undergo SRS alone. We did a randomised controlled trial to test our prediction...
  56. ncbi Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy...
  57. ncbi Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  58. ncbi Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
    ..We chose to measure these molecules in the cerebrospinal fluid (CSF) of melanoma, breast, and lung cancer patients being evaluated for neoplastic meningitis (NM)...
  59. ncbi Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer
    Xiaoqun Dong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Gastroenterology 139:464-73, 473.e1-3. 2010
    ..We examined whether IGF-axis gene variants are associated with clinical outcomes in pancreatic cancer...
  60. ncbi Mechanisms of action of rapamycin in gliomas
    Amy B Heimberger
    Brain Tumor Center, Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 7:1-11. 2005
    ....
  61. ncbi Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
    Vinay K Puduvalli
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 65:259-66. 2003
    ..In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival...
  62. ncbi Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets
    Gregory N Fuller
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Brain Pathol 12:108-16. 2002
    ....
  63. ncbi Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity
    Ilya Shmulevich
    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2069-75. 2002
    ..The authors also identified genes that are expressed differentially in tumor and normal tissue...
  64. ncbi Complementary and alternative medicine use and quality of life in patients with primary brain tumors
    Terri Armstrong
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Pain Symptom Manage 32:148-54. 2006
    ..This may be especially relevant in those patients with higher functional status participating in clinical trials...
  65. ncbi A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
    W F Symmans
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Endocr Relat Cancer 12:1059-69. 2005
    ..036). GABApi gene expression is increased in breast cancers of immature (undifferentiated) cell type and is significantly associated with shorter lifetime history of breastfeeding and with high-grade breast cancer in Hispanic women...
  66. ncbi Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma
    Hiroshi Aoki
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 13:6603-9. 2007
    ..Thus, we examined patterns of Pak1 expression in glioblastoma and sought to determine whether the level of phosphorylated Pak1 in glioblastoma cells is associated with patient survival time...
  67. ncbi Reproducibility of gene expression signature-based predictions in replicate experiments
    Keith Anderson
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77230-1439, USA
    Clin Cancer Res 12:1721-7. 2006
    ..016), respectively. CONCLUSION: Gene expression results obtained with Affymetrix U133A chips are highly reproducible within and across two high-volume laboratories. Pharmacogenomic predictions yielded >90% agreement in replicate data...
  68. ncbi Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation
    Luo Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1627-32. 2006
    ..We investigated whether hTERT MNS16A variant genotype predicted survival in GBM patients...
  69. ncbi Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells
    T Yokoyama
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gene Ther 15:1233-9. 2008
    ..The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma...
  70. ncbi Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcomes theoretical limitations of Cox proportional hazards regression
    M W Kattan
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Comput Biomed Res 31:363-73. 1998
    ..Further research is necessary to predict which technique will do best a priori and to assess the magnitude of superiority...
  71. ncbi CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma
    Silvana C Faria
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    AJR Am J Roentgenol 189:378-85. 2007
    ..Our objective was to use functional CT to evaluate the effects of thalidomide in patients with metastatic renal cell carcinoma...
  72. ncbi Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4442-8. 2008
    ..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site...
  73. ncbi Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  74. ncbi Learning curves in classification with microarray data
    Kenneth R Hess
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    Semin Oncol 37:65-8. 2010
    ..It is important to employ an algorithm that uses the predictive information efficiently, but with a modest number of training samples (>50), learning curves can be used to assess the predictive efficiency of classification algorithms...
  75. ncbi Expression of metastasis-related genes in human epithelial ovarian tumors
    Carlos A Herrera
    Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 20:5-13. 2002
    ..0005). Multivariate analysis of overall survival showed that the MMP:E-cadherin ratio was a significant independent prognostic factor, even after adjustment for known prognostic factors, such as histology, stage, and age...
  76. ncbi Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response
    Darren W Davis
    Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:955-60. 2003
    ..CONCLUSIONS: If the results can be validated in a larger patient cohort, the method could be used to "tailor" therapy to optimize benefit in a patient-specific fashion...
  77. ncbi Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin
    Guido M Sclabas
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2485-90. 2005
    ..Aspirin-mediated antiinflammatory approaches might be an effective strategy to prevent pancreatic carcinoma...
  78. ncbi Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients
    P W Pisters
    Pancreatic Tumor Study Group, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Ann Surg 234:47-55. 2001
    ..To examine the relationship between preoperative biliary drainage and the morbidity and mortality associated with pancreaticoduodenectomy...
  79. ncbi Surgery for abdominal metastases of cutaneous melanoma
    H Gutman
    Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    World J Surg 25:750-8. 2001
    ..Less than complete resection can provide durable palliation...
  80. ncbi "Ditzels" on chest CT: survey of members of the Society of Thoracic Radiology
    R F Munden
    Department of Radiology, Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 057, Houston, TX 77030, USA
    AJR Am J Roentgenol 176:1363-9. 2001
    ..Location in an area considered endemic for granulomatous disease and years of experience influenced decisions...
  81. ncbi Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme
    V A Levin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 6:3878-84. 2000
    ..PCV is still ongoing and hopefully will yield more encouraging results...
  82. ncbi Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta)
    L R Hill
    Department of Veterinary Sciences, The University of Texas M D Anderson Cancer Center, Bastrop 78602, USA
    J Med Primatol 30:56-60. 2001
    ..We found that, regardless of age, sex, weight, or skeletal size, all normal adult rhesus monkeys generally have similar-sized kidneys...
  83. ncbi Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis
    T Sano
    Department of Neuro Oncology, The Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 59:1820-4. 1999
    ..The combination of these results suggest that, in addition to molecular alterations affecting the gene, altered expression of MMAC/PTEN may play a significant role in the progression of GBM and patient outcome...
  84. ncbi Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
    Laura Harstad
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 10:1010-8. 2008
    ..This retrospective analysis confirmed the dismal prognosis associated with LM. The amount of CNS tumor burden at the time of diagnosis of LM did not inversely correlate with survival outcomes, contrary to our hypothesis...
  85. ncbi Comparing survival curves using an easy to interpret statistic
    Kenneth R Hess
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Cancer Res 16:4912-3. 2010
    ..It is a useful and convenient measure for assessing differences between survival curves. Software for computing the statistic is readily available on the Internet...
  86. ncbi Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
    Henry Q Xiong
    Center for Cancer and Blood Disorders, Fort Worth, Texas, USA
    Cancer 113:2046-52. 2008
    ..A phase 2 trial was conducted to explore the efficacy of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer previously who were treated with gemcitabine...
  87. ncbi Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  88. ncbi Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables
    Yi Hong Zhou
    Department of Neurobiology and Developmental Sciences, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Neuro Oncol 7:485-94. 2005
    ..This finding suggests that the expression of IGFBP2 is associated with pathways activated specifically in GBMs that result in enhancing invasiveness and angiogenesis...
  89. ncbi Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips
    James Stec
    Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    J Mol Diagn 7:357-67. 2005
    ..We conclude that multigene predictors optimized for one platform lose accuracy when applied to data from another platform due to missing genes and sequence differences in probes that result in differing measurements for the same gene...
  90. ncbi PAX6 suppresses growth of human glioblastoma cells
    Yi Hong Zhou
    Department of Neurobiology and Developmental Sciences, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 753, Little Rock, AR 72205, USA
    J Neurooncol 71:223-9. 2005
    ..Thus it is interesting to determine if repression of PAX6 expression is involved in anti-tumor suppression function in GBM...
  91. ncbi Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  92. ncbi O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
    S Clifford Schold
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Neuro Oncol 6:28-32. 2004
    ..We conclude that a BG dose of 120 mg/m(2) given 6 h before an alkylating drug would be effective in suppressing AGT and possibly potentiating the cytotoxic effects of the drug...
  93. ncbi Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas
    Funda Meric
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1120-6. 2002
    ..CONCLUSIONS: The NeoCT regimens used in this study resulted in tumor shrinkage sufficient to impact surgical therapy in a few patients. However, radiographic response predicted improved local control and overall survival rate...
  94. ncbi ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas
    Douglas B Evans
    Ann Surg 236:694; author reply 694-6. 2002
  95. ncbi Identification of combination gene sets for glioma classification
    Seungchan Kim
    Department of Electrical Engineering, Texas A and M University, College Station, Texas 77840, USA
    Mol Cancer Ther 1:1229-36. 2002
    ..Two-gene and three-gene combinations thus provide robust classifiers possessing the potential to translate expression microarray results into diagnostic histopathological assays for clinical utilization...
  96. ncbi Spinal cord protection during aortic cross clamping: retrograde venous spinal cord perfusion, distal aortic perfusion, and cerebrospinal fluid drainage
    Anders Winnerkvist
    Department of Cardiothoracic and Vascular Surgery, University of Texas Health Sciences Center Medical School, Memorial Hermann Hospital, Houston 77030, USA
    Scand Cardiovasc J 36:6-10. 2002
    ..We then examined the clinical feasibility of RVP, DAP, and CSFD...